Pharmacological Treatment of Schizophrenia and Co-Occurring Substance Use Disorders

被引:0
作者
David A. Smelson
Lisa Dixon
Thomas Craig
Stephen Remolina
Steven L. Batki
Noosha Niv
Richard Owen
机构
[1] Edith Nourse Rogers VA Hospital,Department of Veterans Affairs
[2] University of Massachusetts Medical School,Department of Psychiatry
[3] Department of Veterans Affairs VISN 4 MIRECC,Department of Veterans Affairs
[4] University of Maryland,Center for Mental Healthcare & Outcomes Research
[5] American Psychiatric Association,undefined
[6] New Jersey Health Care System,undefined
[7] University of California,undefined
[8] San Francisco VA Medical Center,undefined
[9] SUNY Upstate Medical University,undefined
[10] University of California,undefined
[11] Central Arkansas Veterans Health Care System,undefined
来源
CNS Drugs | 2008年 / 22卷
关键词
Schizophrenia; Clozapine; Risperidone; Olanzapine; Naltrexone;
D O I
暂无
中图分类号
学科分类号
摘要
Substance abuse among individuals with schizophrenia is common and is often associated with poor clinical outcomes. Comprehensive, integrated pharmacological and psychosocial treatments have been shown to improve these outcomes. While a growing number of studies suggest that second-generation antipsychotic medications may have beneficial effects on the treatment of co-occurring sub-stance use disorders, this review suggests that the literature is still in its infancy. Few existing well controlled trials support greater efficacy of second-generation antipsychotics compared with first-generation antipsychotics or any particular second-generation antipsychotic. This article focuses on and reviews studies involving US FDA-approved medications for co-occurring substance abuse problems among individuals with schizophrenia.
引用
收藏
页码:903 / 916
页数:13
相关论文
共 50 条
  • [1] Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders
    Akerman S.C.
    Brunette M.F.
    Noordsy D.L.
    Green A.I.
    Current Addiction Reports, 2014, 1 (4) : 251 - 260
  • [2] Pharmacotherapy for schizophrenia and co-occurring substance use disorders
    Green, Alan I.
    NEUROTOXICITY RESEARCH, 2007, 11 (01) : 33 - 39
  • [3] Pharmacotherapy for schizophrenia and co-occurring substance use disorders
    Alan I. Green
    Neurotoxicity Research, 2007, 11 : 33 - 39
  • [4] Treatment of Co-Occurring Psychotic and Substance Use Disorders
    Mueser, Kim T.
    Gingerich, Susan
    SOCIAL WORK IN PUBLIC HEALTH, 2013, 28 (3-4) : 424 - 439
  • [5] Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders
    Brunette, Mary F.
    Drake, Robert E.
    Xie, Haiyi
    McHugo, Gregory J.
    Green, Alan I.
    SCHIZOPHRENIA BULLETIN, 2006, 32 (04) : 637 - 643
  • [6] Family Therapy for Schizophrenia: Co-Occurring Psychotic and Substance Use Disorders
    Gottlieb, Jennifer D.
    Mueser, Kim T.
    Glynn, Shirley M.
    JOURNAL OF CLINICAL PSYCHOLOGY, 2012, 68 (05) : 490 - 501
  • [7] Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
    Coles, Alexandria S.
    Knezevic, Dunja
    George, Tony P.
    Correll, Christoph U.
    Kane, John M.
    Castle, David
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [8] Co-occurring medical and substance use disorders in patients with schizophrenia: a systematic review
    Ayano, Getinet
    INTERNATIONAL JOURNAL OF MENTAL HEALTH, 2019, 48 (01) : 62 - 76
  • [9] Treatment of substance use disorders with co-occurring severe mental health disorders
    Murthy, Pratima
    Mahadevan, Jayant
    Chand, Prabhat K.
    CURRENT OPINION IN PSYCHIATRY, 2019, 32 (04) : 293 - 299
  • [10] Schizophrenia and co-occurring substance use disorder: Reward, olfaction and clozapine
    Mesholam-Gately, Raquelle I.
    Gibson, Lauren E.
    Seidman, Larry J.
    Green, Alan I.
    SCHIZOPHRENIA RESEARCH, 2014, 155 (1-3) : 45 - 51